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ABSTRACT 
 Glioblastoma multiforme (GBM) is the most common and malignant primary brain 
tumor in adults, characterized by aggressive growth, limited response to therapy, and 
inexorable recurrence. Because of the extremely unfavorable prognosis of GBM, it is 
important to develop more effective diagnostic and therapeutic strategies based on 
biologically and clinically relevant patient stratification systems. Analyzing a collection of 
patient-derived GBM stem-like cells (GSCs) by gene expression profiling, nuclear magnetic 
resonance (NMR) spectroscopy and signal transduction pathway activation, we identified two 
GSC clusters characterized by different clinical features. Due to the widely documented role 
played by microRNAs (miRNAs) in the tumorigenesis process, in this study we explored 
whether these two GBM patient subtypes could also be discriminated by different miRNA 
signatures. Global miRNA expression pattern was analyzed by oblique principal component 
(OPC) analysis and principal component analysis (PCA). By a combined inferential strategy 
on PCA results, we identified a reduced set of three miRNAs – miR-23a, miR-27a and miR-
9* (miR-9-3p) – able to discriminate the proneural- and mesenchymal-like GSC phenotypes 
as well as mesenchymal and proneural subtypes of primary GBM included in The Cancer 
Genome Atlas (TCGA) dataset. Kaplan-Meier analysis showed a significant correlation 
between the selected miRNAs and overall survival in 429 GBM specimens from TCGA-
identifying patients who had an unfavorable outcome. The survival prognostic capability of 
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the three miRNA signatures could have important implications for the understanding of the 
biology of GBM subtypes and could be useful in patient stratification to facilitate 
interpretation of results from clinical trials. 
 
 
1. INTRODUCTION  
 
 Glioblastoma multiforme (GBM) is the most frequent and malignant primary adult 
brain tumor. Standard GBM treatment includes maximal safe surgical resection followed by 
combined radiotherapy and chemotherapy with the DNA methylating agent temozolomide 
(TMZ) (Stupp et al., 2005). Despite continuous improvements in the treatment of GBM 
during the past decade, these tumors are still associated with a poor prognosis and rare long-
term survival (Wen and Kesari, 2008). 
 Incurable GBM is characterized by uncontrolled cellular proliferation, robust 
angiogenesis, intense resistance to apoptosis, diffuse infiltration, propensity for necrosis and 
genomic instability. Moreover, it exhibits a high degree of intra- and inter-tumor 
heterogeneity (Dunn et al., 2012).  
 Genomic profiling, chromosomal number variations and abnormalities in DNA 
methylation have been used to define four subtypes of GBM, that include the pro-neural 
(oligodendrocytic signature), neural (oligodendrocytic, astrocytic and neural signature), 
mesenchymal (cultured astroglial signature) and classical (astrocytic signature) subtype 
(Verhaak et al., 2010). 
 Increasing evidence has led to the identification of a subpopulation of cells displaying 
stem-like properties reminiscent of normal stem cells, called tumor-initiating cells or GBM 
stem-like cells (GSCs), that are believed to play a fundamental role in tumor resistance to 
chemo- or radiotherapy as well as in tumor recurrence (Singh et al., 2004). GSCs can be 
isolated to generate cell lines characterized by self-renewing, multi-potency, and high 
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tumorigenic ability and are reported to recapitulate the genotype, gene expression patterns 
and in vivo biology of human GBM more closely than many commonly utilized glioma cell 
lines (Ernst et al., 2009; Lee et al., 2006). The availability of cell lines that represent a more 
reliable model for understanding the biology of primary human tumors, may help to identify 
cues for targeted therapies (Piccirillo et al., 2015). 
 One of the hallmarks of cancer is the defect in the regulatory circuits that control 
normal cell proliferation and homeostasis (Hanahan and Weinberg, 2011). Through the 
ability to regulate a large number of genes, microRNAs (miRNAs), a class of short non-
coding RNAs, has been shown to control diverse oncogenic signaling pathways including cell 
proliferation, cell cycle regulation, apoptosis, invasion, glioma stem cells behavior, and 
angiogenesis. Dysregulated miRNAs are considered to be essential players in carcinogenesis, 
and thus potential therapeutic targets (Mizoguchi et al., 2013). Deregulation of miRNAs can 
affect carcinogenesis if their target mRNAs are encoded by oncogenes or tumor suppressor 
genes (Lages et al., 2012); overexpression, silencing or switching off specific miRNAs have 
been described in carcinogenesis of GBM (Brower et al., 2014; Floyd and Purow, 2014; 
Henriksen et al., 2014). Silencing or down-regulation may result from deletion of a 
chromosomal region, epigenetic silencing, or defects in their biogenesis whereas increased 
expression of mature miRNA may occur as a consequence of transcriptional activation or 
amplification of the miRNA encoding gene. 
 In the attempt to find druggable signaling pathways, we previously analyzed a 
collection of nineteen patient-derived GSCs by gene expression profiling, NMR spectroscopy 
and phosphoproteomic analysis of the signal transduction pathway (Marziali et al., 2016). We 
identified two GSC clusters, resembling the GSf and GSr groups described by Schulte 
(Schulte et al., 2011), though with distinct molecular signatures. Based on gene expression, 
NMR spectroscopy and phosphoproteomic data, we found that the GSf-like and GSr-like 
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clusters are characterized by a "pro-neural-" and "mesenchymal"-like signature, respectively, 
similar to those described by Verhaak et al. (Verhaak et al., 2010). Significant overlaps with 
the other two GBM subtypes (i.e. neural and classic) were not observed in our GSC 
collection. Phosphoproteomic analysis showed that the GSf-like signature is characterized by 
a significant increase in SRC, Mitogen Activated Protein Kinase (MAPK), and Insulin-like 
Growth Factor-Receptor (IGF1-R/IR), whereas GSr-like lines displayed increased levels of 
phosphorylated proteins associated with the mammalian Target of Rapamycin (mTOR) 
pathway and a strong activation of downstream targets of the Epidermal Growth Factor 
Receptor (EGFR) (Marziali et al., 2016). 
 Classifying GBM patients included in The Cancer Genome Atlas (TCGA) based on 
combined expression patterns of the two RPPA endpoints discriminating GSf- and GSr-like 
phenotypes (i.e. SRC and RPS6, respectively), we showed that TCGA GBM patients with 
GSr-like features display a significantly shorter overall survival (Marziali et al., 2016).  
 To further dissect the molecular biology of GSCs, in the present study we analyzed 
miRNA expression profile by microarray analysis to identify miRNAs differentially 
expressed between GSf- and GSr-like sample groups. A reduced set of three miRNAs, able to 
discriminate GSf- and GSr-like GSC phenotypes as well as mesenchymal and proneural 
GBM patient subtypes with different clinical outcomes was identified.  
 
2. MATERIALS AND METHODS 
2.1. Clinical material and tumor characterization 
 Glioblastoma samples were harvested from 35 out of 109 consecutive patients who 
underwent craniotomy at the Institute of Neurosurgery, Catholic University of Rome. All 
patients provided written informed consent according to research proposals approved by the 
Institutional Ethical Committee. Clinical and pathological features are summarized in 
Supplementary Table S1. Patients were 38 to 80 year-old at diagnosis (median, 58 yrs); 26 
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were men and 9 were women. The expression of the proliferation marker Ki67, PTEN, 
Vascular Endothelial Growth Factor (VEGF) and EGFRvIII were characterized on tumor 
specimens by immunohistochemistry on deparaffinized sections as previously described 
(Martini et al., 2013; Martini et al., 2008; Montano et al., 2011; Pallini et al., 2008). MGMT 
promoter methylation patterns by methylation-specific PCR and isocitrate dehydrogenase 
(IDH)1/2 mutation state were assessed on genomic DNA extracted from paraffin-embedded 
tissue as previously described (Horbinski et al., 2009; Pallini et al., 2008). OS was calculated 
from the date of surgery where a diagnosis of GBM was established, to death. PFS was 
determined from the date of surgery until progression or death (Wen et al., 2010). After 
surgery, the patients received radiotherapy and concomitant TMZ followed by six cycles of 
adjuvant TMZ according to the Stupp protocol (Stupp et al., 2005; Wen et al., 2010). 
 Cox analysis was used for hazard ratio and 95% confidence interval determination. 
All p-values are based on two-tailed tests and differences were considered significant when 
p<0.05. StatView ver5.0 was used (SAS Institute, Cary, NC). 
2.2. Glioblastoma stem-like cell cultures 
 GSCs were isolated through mechanical dissociation of the tumor tissue and cultured 
in a serum-free medium supplemented with epidermal growth factor (EGF) and basic 
fibroblast growth factor (bFGF) as previously described (Pallini et al., 2008). Cell lines 
actively proliferating required 3 to 4 weeks to be established. In these conditions, cells grow 
as clusters of undifferentiated cells, as indicated by morphology and expression of stem cell 
markers such as CD133 and SOX2 (Supplementary Table S2). Stem cell marker expression 
was assessed by flow cytometry using a Canto analyzer (Becton Dickinson, Milan, Italy) 
using AC133-PE antibody (Miltenyi Biotec, Bologna, Italy) and PerCP-CyTM 5.5 mouse anti-
Sox2 (BD, Becton Dickinson, Milan, Italy) for CD133 and Sox2, respectively. Viable cells 
were identified using 7-amino actinomycin D (7AAD; Sigma Aldrich, St. Louis, MO). To 
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assess clonogenicity, viable cells were dispensed at different densities (1-3-10 cells/well) in 
96 well plates by cell sorting (FACS Aria, Becton Dickinson) (Supplementary Table S2). 
After 10-14 days, wells with growing clones were enumerated, and results were analysed by 
Extreme Limiting Dilution Assay (ELDA) software (Hu and Smyth, 2009). The in vivo 
tumorigenic potential of GBM neurospheres was assayed by intracranial or subcutaneous cell 
injection in immunocompromised mice in 30 out of 37 GSC lines. GBM neurospheres were 
able to generate a tumor identical to the human tumor in antigen expression and histological 
tissue organization. GSC lines were validated by Short Tandem Repeat (STR) DNA 
fingerprinting as previously described (Lulli et al., 2015). 
2.3. Microarrays and Real-Time PCR  
 To analyze GSC miRNA expression total RNA was prepared using TRIzol Reagent 
(Invitrogen Life Technologies, Carlsbad, CA, USA). RNA was labeled and hybridized to the 
Agilent-019118 array following the manufacturer's instructions. Microarray analysis was 
performed as previously described (Felli et al., 2010). 
For Real-time PCR, fifty nanograms of RNA were reverse transcribed with TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). Real-time 
PCR for miR-23a-3p (miRBase ID MIMAT0000078), miR-27a-3p (miRBase ID 
MIMAT0000084) and miR-9-3p (miRBase ID MIMAT0000442), were performed using 
TaqMan® MicroRNA Assays protocol (assay ID 000399, ID 000408, ID 002231, Applied 
Biosystems). All reactions were run in duplicate. Normalization was performed by using 
RNU6B primer kit (ID 001093, Applied Biosystems). RT-PCR was performed using an ABI 
Prism 7900 Sequence Detector (Applied Biosystems). 
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2.4. Statistical Methods  
 In order to single out an effective miRNA signature for the GSf/GSr discrimination 
we applied a four-step strategy:  
i) clustering of the variables (miRNA expression profiles) by means of Oblique Principal 
Component Analysis (OPC) to single out (if any) a profile partition consistent with the 
GSf/GSr classification. OPC (Sethi, 1971) is a divisive clustering that partitions the variables 
of a data set into maximally internally correlated clusters. The partition stops when the ratio: 
intra-cluster/inter-cluster correlation reaches a maximum. If this purely data-driven partition 
matches the GSf/GSr a priori classification we have a proof-of-concept of the discrimination 
of the two sub-types in the miRNA space; ii) application of Principal Component Analysis 
(PCA) on the data set having miRNA as statistical units and samples (miRNA profiles) as 
variables. The seven miRNAs endowed with the highest scores on the a posteriori emerging 
discriminant component were selected. This data-driven strategy allows for the elimination of 
overfitting problems (Napoletani et al., 2010) by concentrating on a purely unsupervised 
selection of miRNAs. After this step, we further refined our choice by the computation of (iii) 
mutual Pearson correlations between selected miRNAs on a transposed (statistical units = cell 
lines, variables = selected miRNA species) subset of the original data matrix to eliminate 
redundant miRNA species (only one of strongly correlated pairs selected on the basis of their 
statistical significance as for GSf/GSr classification).  
The last step (iv) was the application of Linear Discriminant Analysis (LDA) based on the 
three miRNA species previously selected on independent data sets so to check their 
classification ability at both statistical (training set) and predictive (test set) levels. 
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3. RESULTS  
3.1. Multidimensional analysis of GSf- and GSr-like miRNA profiles 
 Analyzing a collection of nineteen GSC lines derived from seventeen GBM patients 
(from two of these, GSC lines from different tumor regions were isolated), by complementary 
molecular approaches, we recently identified two GSC clusters: one characterized by a 
proneural-like phenotype (GSf-like) and the other showing a mesenchymal-like phenotype 
(GSr-like) (Marziali et al., 2016).  
 To further examine the molecular biology of our GSC lines we analyzed mature 
miRNA expression using a microarray platform. Following background subtraction and 
quartile normalization, the global miRNA expression pattern was analyzed by oblique 
principal component analysis (OPC), a divisive variable clustering technique (Sethi, 1971). 
This analysis gave rise to a two cluster optimal solution (Table 1) that exactly mirrors the a 
priori GSf-/GSr-like classification except for line GSC#83.2. It is worth noting that, being 
OPC a completely unsupervised procedure and the GSf-/GSr-like label added a posteriori, 
the classification does not suffer from overfitting problems. The misclassified line (shown in 
italics in Table 1) lies on the border between the two clusters having an R-square with its own 
cluster (Own Cluster R-square = 0.79) of the same order of magnitude of the R-square with 
the other class (R-square = 0.72). The two cluster partition explains the 84.6% of total 
variance (Proportion of variance Explained, bolded in the Table 1) while, considering all the 
samples as part of the same group (one cluster solution), it accounts for 82.5% of total 
information. Thus, all the samples, besides their GSf-/GSr-like character, are largely invariant, 
pointing to a shared ideal miRNA profile characteristic of the tissue.  
 Having verified the ability of the entire miRNA profile to correctly discriminate the 
two GBM subtypes we checked for the existence of a single score able to select the best 
linear combination of miRNA species endowed with such discriminant ability. We faced this 
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task by analyzing the same data set by a Principal Component Analysis (PCA) which allows 
for the projection of the initial 19 dimensions data set into a reduced space spanned by 
mutually independent axes (principal components) explaining the relevant (signal-like) part 
of total variance of the system. Differently from OPC that partitions the variables into disjoint 
sets, PCA is a spectral method (Preisendorfer et al., 1988) and this implies that each miRNA 
species has a score relative to each component while, at the same time, each sample has a 
peculiar correlation (loading) with all the extracted components. 
 PCA showed a clear clustering of GSC cell lines and confirmed separation between 
GSf- and GSr-like samples (Figure 1, top panel). PCA suggests a two-component solution as 
a bona fide reliable reconstruction of the 19 sample space. The percent of variation explained 
by the first two components (Factor 1, Factor 2) is reported in Table 2a. The first component 
(Factor 1) explains the far major part of system variation (77% of total variance explained), 
while the second accounts for 8.5% of total variance. Globally the two-component solution 
accounts for 85% of total information. Pearson correlation coefficients of the original 
variables (samples) with the extracted components constitute the factor-loading pattern 
(Table 2b) and allow to assign a meaning to the Factors.  
Factor 1 is a ‘size’ component (Jolicoeur and Mosimann, 1960): all the samples have values 
close to unity loadings, in line with the existence of a ‘common miRNA ideal profile’ shared 
by all the samples, possibly due to the common tissue origin. Factor 2 is a ‘shape’ component 
mirroring the ‘GSf-/GSr-like’ axis: all the GSf-like samples have negative loadings with 
Factor 2 while GSr-like loadings are positive. Thus, miRNAs with high scores on Factor 2 
point to the GSr-like phenotype whereas miRNAs with low scores identify the GSf-like 
subtype. Results of PCA for both samples (loading space) and miRNAs (score space) are 
shown in Figure 1. 
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3.2. A set of three miRNAs discriminates between GSf- and GSr-like GSC subtypes 
 Focusing on miRNAs endowed with the maximal relevance of the discriminating 
component (Factor 2), we established a threshold (Figure 1, bottom panel) corresponding to a 
score > 5 in absolute value to set a reduced signature. Since principal components have by 
construction zero mean and unit standard deviation, they correspond to z-scores, thus a 
threshold of 5 corresponds to a p < 0.00001 as far as the influence of Factor 2 (i.e. the 
discriminating component) on the selected miRNA species is concerned. Seven miRNAs 
species emerged from the application of the above threshold. The Pearson correlation 
coefficients between these seven miRNA species were computed to eliminate redundant 
miRNAs (two miRNAs having near to unity correlation need not be both inserted in the 
signature, given they carry largely redundant information). Table 3 reports the miRNAs 
correlation matrix (bolded near to unity correlations). Correlations near to unity correspond to 
miRNAs already known to be structurally related (mature sequences of miR-23a, miR-27a, 
miR-24-2 derived from a common pri-miRNA transcript encoded by miR-23a/miR27a/miR-
24-2 cluster on chromosome 19, miR-9 and  miR-9* originate from the opposite strand of the 
same precursor) (Liang et al., 2014). As expected, a statistically significant difference 
between the two groups was observed for all the seven miRNAs.  
 In order to select, for each redundant pair, the ‘best representative’ species, miRNAs 
were ordered in terms of their t-test statistics values (Table 4) and those with higher t-value 
were chosen (bolded in Table 4). At the end of this procedure a 3 miRNA signature (miR-23a, 
miR-27a and miR-9*), able to correctly cluster 18 out of 19 GSC lines collection in two 
subtypes emerged (Table 5). 
 To check the generalization ability of the selected signature, we analyzed the 
expression levels of miR-23a, miR-27a and miR-9* (now identified as miR-9-3p, 
www.mirbase.org) in both our sample set and in 18 newly established GSC lines by real-time 
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polymerase chain reaction (RT-PCR) (Supplementary Table S3), reaching a total of 37 GSC 
lines analyzed.  
 All the discriminant analyses were performed establishing a training set of 16 out of 
19 samples of known phenotype (7 GSr-like, 9 GSf-like). This set was selected to build the 
linear discriminant function, which in turn was used for predicting an independent test set 
(n=21; i.e. the 18 new GSC and the 3 remaining GSC lines previously analyzed). All the 
analyses made use of the same signature. Each discriminant analysis is reported in terms of 
its performance on both training and test sets by means of the relative confusion matrixes 
(Table 6). This analysis identified 7 out of 21 GSC lines as GSr-like subtype and the 
remaining as GSf-like subtype. 
 To confirm the predictive potential of the three miRNAs to discriminate between GSf- 
and GSr-like subtypes, the metabolite profiles of the 18 newly established GSC lines were 
analyzed by 1H NMR spectroscopy. We previously demonstrated that the GSf- and GSr-like 
clusters are differentiated by NMR spectroscopy profiles: the GSf-like, characterized by 
metabolites involved in the production of neurotransmitters such as NAA and GABA, with a 
prevalent neuronal metabolism; the GSr-like, characterized by lack of NAA and GABA and 
by high lipids, indicative of a prevalent astroglial-like metabolism (Marziali et al., 2016). 
Unsupervised cluster analysis on all GSC lines clearly separated the samples in the two 
clusters (Figure 2). According to NMR classification, the three miRNA signature was able to 
correctly clusterize 20 out of 21 samples belonging to the test set confirming the reliability of 
the miRNA signature in classifying GSC subtypes (Table 6 and Figure 2).  
 
3.3. Patient clinical features and the three miRNA signature  
 Univariate analysis in all our patient cohort (n=35), showed that post-operative 
Karnofsky Performance Status (KPS) (<70 vs > 70), O6-methylguanine-DNA 
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methyltransferase (MGMT) promoter methylation, and Phosphatase and Tensin Homolog 
(PTEN) expression were significantly associated with Overall Survival (OS) (p=0.0092, 
p=0.0167, and p=0.0284, respectively; log rank test; Supplementary Table S4). Post-
operative KPS>70, MGMT promoter methylation, and PTEN expression showed prognostic 
value also for Progression Free Survival (PFS) (p=0.0214, p=0.0440, and p=0.0485, 
respectively; log rank test; Supplementary Table S4). To analyze possible association of 
miRNA signature with clinical and pathological parameters of the donor patients, we 
distinguished GBMs that generated GSf-like cells (Group A, n=22) from those generating 
GSr-like cells (Group B, n=13) (Supplementary Table S5). Patients of group A and group B 
were homogeneous for the clinical and molecular features that hold prognostic value, such as 
age, extent of tumor resection, KPS, and MGMT methylation (Supplementary Table S1). As 
previously described (Marziali et al., 2016), EGFRvIII expression was more frequent in 
tumors generating GSr-like cultures than in those generating GSf-like cultures. There were no 
significant differences in OS and PFS between GSf- and GSr-like generating tumors (median 
OS=9 and 8 months, median PFS=5 and 4 months, p=0.5593 and 0.4921, respectively; log-
rank test; Supplementary Table S5).  
 
3.4. The three miRNA signature discriminates between Proneural and Mesenchymal 
subtypes in the TCGA cohort 
 Taking into account the potential bias of information obtained from our limited GSC 
samples, we tested the reliability of the signature in classifying GBM patients from 
completely independent sources such as the large cohort of GBM patients from TCGA. Thus, 
we explored the expression of miR-23a, miR-27a and miR-9-3p by using the Glioblastoma 
Bio Discovery Portal (GBM-BioDP software platform, http://gbm-biodp.nci.nih.gov). 
miRNA expression data were available for 429 patients, classified into the four subtypes: 
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proneural (P), neural (N), classical (C) and mesenchymal (M), as described by Verhaak and 
colleagues (Verhaak et al., 2010). As previously reported (Marziali et al., 2016), the GSf-like 
and GSr-like clusters are characterized by a “proneural” and a “mesenchymal-like” 
expression signature, respectively. Thus, we selected P (97 patients) and M (108 patients) 
from the 429 patients of the TCGA database and we performed the discriminant analyses 
according to the same scheme used for the 37 GSC lines described above. We defined a 
training set of 129 out of 205 patients of known subtype (70 M and 59 P) to build the linear 
discriminant function, which in turn was used for predicting an independent test set (n=76). 
As shown in Table 7, the analysis was able to correctly classify 30 out of 38 M patients and 
31 out of 38 P patients confirming the high predictive potential of the three miRNA signature.  
 To further validate the ability of miR-23a, miR-27a and miR-9-3p in discriminating 
between M and P GBM subtypes in the cohort of TCGA patients the GBM-BioDP software 
platform was used (Celiku et al., 2014). We found that both miR-23a and 27a were 
significantly higher in the M versus P subtype whereas miR-9-3p expression was 
significantly higher in the P versus M subtype confirming a role for these three miRNAs in 
patient stratification (Figure 3A). Similarly, using miR-23a, miR-27a and miR-9-3p 
expression levels of our collection of GSC lines, we found that miR-9-3p expression was 
significantly higher in the GSf- versus GSr-like subtype whereas, both miR-23a and miR-27a 
were significantly higher in GSr- versus GSf-like subtype (Figure 3B), confirming the 
“proneural” and “mesenchymal-like” expression signature of the GSC subtype, respectively.  
 
3.5. The three miRNA signature identifies two subtypes with different prognosis in the 
TCGA cohort of GBM patients  
In order to investigate the prognostic value of the three miRNA signature we evaluated 
whether miRNA-based classification correlated with clinical outcomes of the TCGA patients. 
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We initially classified the patients categorized as M and P subtypes, according to Verhaak’s 
criteria, for which survival data were available (n=169 out of 205). As shown in Figure 4A, 
the prognoses of the patients classified as GSr-like, were significantly worse than those 
classified as GSf-like (p=0.0032). Then, to assess the generalized power of the three miRNA 
based classification for predicting patient clinical outcome, we analyzed the whole cohort of 
TCGA patients, for which survival and miRNA expression data were available (n=429), 
irrespective of the Verhaak subtype classification. A training set of 177 patients of known 
subtype (i.e. 93 M and 84 P) was defined to build the linear discriminant function used to 
classify the remaining 252 patients (independent test set). TCGA patients identified as C 
subtype were equally distributed between GSf- and GSr-like subgroups whereas, the majority 
(2:1) of the N patients gathered in the GSf-like subtype. This analysis classified 121 patients 
as GSf-like and 131 as GSr-like subtypes. Kaplan-Meier survival analysis (Figure 4B) 
revealed that the prognoses of patients classified as GSr-like were significantly worse than 
those classified as GSf-like (p=0.042), indicating the three miRNA signature is significantly 
associated with survival.   
 
3.6. Genes involved in cancer and neurodegenerative pathways are the preferential 
targets of the three miRNA signature. 
 To explore the possible biological impact of miR-23a, miR-27a and miR-9-3p in 
GBM, we derived the potential target genes from GB-BioD. The lists of mRNAs correlating 
with selected miRNAs were then analyzed for pathway enrichment analysis by using the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) present in MSigDB (GSEA online tool; 
http://www.broadinstitute.org/gsea/index.jsp). We found that the most significantly enriched 
pathways were related to cancer, apoptosis or focal adhesion. Interestingly, a significant 
association with pathways involved in neurodegenerative disease emerged, suggesting that 
A
cc
ep
te
d 
A
rt
ic
le
Molecular Oncology (2017) © 2017 The Authors. Published by FEBS Press and John Wiley 
& Sons Ltd. 
these three miRNAs may be associated to major neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s diseases in addition to brain malignancies (Figure 5 and 
Supplemantary Table S6). 
  
4. DISCUSSION 
 The identification of the key cellular pathways targeted by mutation during tumor 
progression is a high priority aim in cancer research. Using global gene expression profiling, 
several research groups have categorized GBM into distinct subtypes. The proneural (P) and 
mesenchymal (M) subtypes have been identified as representative classifiers and reported to 
have both prognostic and predictive value (Colman et al., 2010; Freije et al., 2004; Li et al., 
2009; Phillips et al., 2006; Verhaak et al., 2010). 
 To date, classification of GBMs has not become part of clinical practice due mainly to 
the absence of a direct implication in the selection of a more appropriate therapy. However, 
identifying novel genetic signatures to gain better insights into the biology of cancers may 
help to develop novel therapies in the direction of precision medicine. 
 Several studies have reported miRNA profiles in GBM, highlighting the role of 
miRNAs in the progression of this disease and suggesting that miRNA signatures may be 
prognostic indicators of GBM and thus potentially, predict clinical outcome (Barbano et al., 
2014; Fowler et al., 2011; Guan et al., 2015; Kim et al., 2011; Kouri et al., 2015; Lakomy et 
al., 2011; Pang et al., 2015; Zhang et al., 2016). 
Here, we performed miRNA expression profiling of a collection of patients-derived GSC 
culture and identified a three miRNA signature (miR-23a–3p, miR-27a-3p and miR-9-3p) 
able to classify the cohort of TCGA GBM patients in two subgroups with significantly 
different overall survival.  
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 In agreement with previous data, the expression of these three miRNAs is 
significantly altered in GBM compared with normal brain tissues (Rao et al., 2010; Visani et 
al., 2014).  
 The TCGA GBM dataset showed decreased miR-9-3p and increased miR-23a and 
miR-27a expression preferentially in GBMs with a mesenchymal expression signature 
associated with a more invasive and aggressive behavior (Phillips et al., 2006). The same 
expression trends of these miRNAs were confirmed in our GSC samples.  
 Mature sequences of miR-23a, miR-27a, miR-24-2 derived from a common pri-
miRNA transcript encoded by mir-23a/mir-27a/mir-24-2 cluster on chromosome 19 (Liang et 
al., 2014). 
 Several studies have shown that miR-23a is involved in the development and 
progression of multiple types of cancers, such as gastrointestinal, colorectal, esophageal 
squamous cell, and lung cancer (Chhabra et al., 2010). Recently, the up-regulation of miR-
23a was found to be associated with glioma. It has been reported that miR-23a acts as a key 
modulator in CREB/PTEN regulated gliomagenesis (Tan et al., 2012). Moreover it promotes 
glioma cell proliferation via regulation of MXI1 (Xu et al., 2013), glioma cell invasion by 
inhibiting the expression of HOXD10 (Hu et al., 2013) and cell growth via targeting 
apoptotic protease activating factor-1 (APAF1) (Lian et al., 2013).   
 The oncogenic role of miR-27a has been confirmed by several experimental studies. 
miR-27a was significantly up-regulated in renal cell carcinoma (Nakata et al., 2015), in 
esophageal cancer (Wu et al., 2015), in gastric adenocarcinoma (Liu et al., 2009) and in 
breast cancer (Mertens-Talcott et al., 2007). miR-27a also contributes to oncogenesis by 
regulating cell cycle progression (Tian et al., 2014). It has recently been shown that miR-27a 
is overexpressed both in human glioma samples and cell lines (Yang et al., 2012).  
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 MiR-9, found to be highly expressed in the brain of vertebrates, has been 
demonstrated to play a role in the development of the nervous system, regulating key genes 
in neurodevelopment by synergizing with its complementary miR-9* (Schraivogel et al., 
2011; Yoo et al., 2009). Both miRNAs may be important GBM mediators via regulation of 
multiple distinct signaling pathways and resistance to chemotherapy. Importantly, it has been 
reported that miR-9 operate as a switch that regulates oligoneural versus mesenchymal 
decisions by suppressing mesenchymal differentiation through downregulation of JAK/STAT 
pathway (Kim et al., 2011). The same study also identified others miRNAs contributing to 
the phenotypic diversity of GBM subtypes indicating that miRNAs may be useful for GBM 
classication allowing for the development of molecular-treatment decisions and more 
accurate prognosis(Kim et al., 2011). 
Recently, the EGFRvIII/Ras/PI3K/AKT axis has been shown to exert its tumorigenic 
influence through the specific inhibition of miR-9 leading to the upregulation of the 
transcription factor FOXP1 thus providing a tumor growth advantage to EGFRvIII-driven 
tumors (Gomez et al., 2014).Interestingly, among the molecular variables characterizing our 
GSC collection, EGFRvIII expression was significantly more frequent in tumors generating 
GSr-like cultures than in those generating GSf-like cultures. However, the median overall 
survival of the donor patients that generated GSr-like cultures compared with that of the 
patients generating GSf-like cultures was not significantly different. The lack of correlation 
with clinical outcome in our patients can be ascribed both to the small number of patients 
included in the study and to limiting factors related to GSC isolation: GSC cultures were 
obtained from only one third of the tumors. This implies that the GSC paradigm cannot be 
applied in a substantial fraction of patients suffering from GBM but mainly to more 
aggressive cases, since median overall and progression free survival were significantly 
shorter in tumors that generated GSC cultures compared with those that did not (Pallini et al., 
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2008).  
 Altogether these data reinforce the concept that miRNAs are important actors in GBM 
carcinogenesis, and thus potential therapeutic targets.  
 
 5. CONCLUSIONS 
A three miRNA signature able to discriminate GSf- and GSr-like GSC phenotypes as well as, 
mesenchymal and proneural GBM patient subtypes was identified, confirming that miRNAs 
can be considered biomarkers for patient stratification. Even though clinical application of 
miRNAs either as potential therapeutics, targets or biomarkers is still at the initial phase of 
development, several ongoing studies are investigating the predictive value of single or 
multiple miRNA levels in oncology. The three miRNA signature grouping TCGA patients in 
two different classes with significant survival differences may be a promising prognostic tool 
that can improve the predictability of tumor aggressiveness. Thus, new knowledge about 
miRNAs in cancer has the potential to indicate new ways to stratify diseases and tailor an 
appropriate therapy to specific GBM patient subsets. 
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FIGURE LEGENDS 
 
Figure 1: Principal component analysis of miRNA expression identifies two distinct clusters 
of GSC-lines largely corresponding to the GSf-like/GSr-like classification described 
previously. Individual GSC samples (top) or miRNAs (bottom) are distributed into bivariate 
spaces spanned by the first two principal component loadings (top panel) and scores (bottom 
panel) respectively. 
 
Figure 2: Classification in two clusters of GSC-lines by miRNA signature reproduces the 
classification based on NMR analysis with the exception of one line. 
 
Figure 3: Box and whiskers plots of miR-9-3p (top), miR-23a (center) and miR-27a (bottom) 
expression in M and P subtype GBM samples extracted from TCGA (A) or in GSC-lines (B). 
Numbers of samples in each group is indicated in brackets. The variability represents the 
range encompassing minimum and maximum values. * and *** indicate a significant (p<0.05 
and p<0.001) difference between the two groups, respectively (Umpaired t test, two-tailed). 
 
Figure 4: Kaplan-Meier analysis shows that  among 169 GBM patients from TCGA 
prognosis was significantly worse in those classified as GSr-like than in those classified as 
GSf-like (p=0.0032) (A). The classification based on miRNA-expression applied to the whole 
cohort of 429 patients for whom survival and miRNA expression data were available, 
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irrespective of the Verhaak subtype classification, revealed that the prognoses of the GSr-like 
patients were significantly worse than those classified as GSf-like (p=0.042) (B). For this 
analysis a training set of 177 out of 429 patients of known subtype (93 M and 84 P) was 
defined to build the linear discriminant function for predicting the GSr- and GSf-like 
subtypes of the independent test set of 252 patients.  
 
Figure 5: Pathway enrichment analysis of mRNA targets of the three miRNAs included in 
the signature indicates a significant association with cell survival, cancer and cell adhesion 
but also with neurodegenerative diseases. 
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Table 1. Cluster summary for the two subtypes 
 
 
Cluster  Variation Proportion Second 
Cluster Members Variation Explained Explained Eigenvalue
1 11 11 9.074497 0.8250 0.6826
2 8 8 6.76652 0.8458 0.5199
R-squared with 
§Own #Next 1-R**2     Variable 
Cluster  Variable Cluster Closest Ratio Label 
Cluster 1 GSC#1 0.9158 0.6729 0.2573 GSF
GSC#28 0.9454 0.5663 0.1260 GSF 
GSC#62 0.8492 0.6188 0.3955 GSF 
GSC#23P 0.9251 0.5786 0.1777 GSF 
GSC#148 0.4918 0.3335 0.7625 GSF 
GSC#83.2 0.7949 0.7244 0.7439 GSR 
GSC#70 0.7282 0.2607 0.3676 GSF 
GSC#67 0.8538 0.5345 0.3142 GSF 
GSC#68 0.9416 0.7630 0.2464 GSF
GSC#76 0.7078 0.6393 0.8101 GSF 
GSC#23C 0.9209 0.6639 0.2354 GSF 
              
Cluster 2 GSC#30PT 0.7142 0.3783 0.4596 GSR 
GSC#151 0.8917 0.6500 0.3094 GSR
GSC#147 0.8619 0.6964 0.4550 GSR
GSC#83 0.8890 0.7076 0.3795 GSR 
GSC#61 0.8113 0.4935 0.3725 GSR 
GSC#30P 0.9034 0.5170 0.2000 GSR 
GSC#74 0.9037 0.5606 0.2191 GSR 
GSC#112 0.7912 0.7170 0.7379 GSR 
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Table 2. Percent of variation (a) and loading pattern (b) of the PCA two components 
 
 
a                   
Eigenvalue Difference Proportion Cumulative
1 14.5695598  12.9073361 0.7668 0.7668
2 1.6622236  0.9878260 0.0875 0.8543
 
 
 
 
b                   
 
  
Factor 1 Factor 2
GSC#1 GSF 0.93869 -0.19860
GSC#28 GSF 0.91768 -0.33740
GSC#62 GSF 0.90229 -0.17376
GSC#30PT GSR 0.74159 0.46038
GSC#23P GSF 0.91457 -0.31932
GSC#148 GSF 0.67795 -0.13114
GSC#83.2 GSR 0.91327 -0.00270
GSC#70 GSF 0.73815 -0.59035
GSC#67 GSF 0.87964 -0.28438
GSC#151 GSR 0.90307 0.26623
GSC#147 GSR 0.91298 0.20288
GSC#83 GSR 0.92311 0.19042
GSC#68 GSF 0.96986 -0.13348
GSC#76 GSF 0.86077 -0.01324
GSC#61 GSR 0.81959 0.41098
GSC#30P GSR 0.85197 0.44001
GSC#74 GSR 0.87068 0.36793
GSC#23C GSF 0.93719 -0.21187
GSC#112 GSR 0.90372 0.09592
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Table 3. Pearson Correlation Coefficients 
 
 
 
  
                      Pearson Correlation Coefficients, N = 19
                        Prob > | r | under H0: Rho=0 
hsa-miR-9* hsa-miR-9 hsa-miR-27a hsa-miR-24 hsa-miR-29b hsa-miR-23a hsa-miR-29a 
hsa-miR-9* 1.00000 0.99076 -0.32515 -0.28202 -0.28583 -0.32931 -0.30315
hsa-miR-9* <.0001 0.17440 0.24210 0.23550 0.16860 0.20710
hsa-miR-9 0.99076 1.00000 -0.35684 -0.29708 -0.32582 -0.35608 -0.33291
hsa-miR-9 <.0001 0.13370 0.21680 0.17340 0.13460 0.16370
hsa-miR-27a -0.32515 -0.35684 1.00000 0.92851 0.41080 0.98329 0.40805
hsa-miR-27a 0.17440 0.13370 <.0001 0.08060 <.0001 0.08290
hsa-miR-24 -0.28202 -0.29708 0.92851 1.00000 0.32381 0.96156 0.31908
hsa-miR-24 0.24210 0.21680 <.0001 0.17620 <.0001 0.18300
hsa-miR-29b -0.28583 -0.32582 0.41080 0.32381 1.00000 0.38931 0.98087
hsa-miR-29b 0.23550 0.17340 0.08060 0.17620 0.09940 <.0001
hsa-miR-23a -0.32931 -0.35608 0.98329 0.96156 0.38931 1.00000 0.38926
hsa-miR-23a 0.16860 0.13460 <.0001 <.0001 0.09940 0.09950
hsa-miR-29a -0.30315 -0.33291 0.40805 0.31908 0.98087 0.38926 1.00000
hsa-miR-29a 0.20710 0.16370 0.08290 0.18300 <.0001 0.09950 
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Table 4. Pearson correlation coefficients ordered in terms of t-test value 
 
 
Variable Method Variances DF t Value Pr > | t |
      
hsa-miR-9* Pooled Equal 17 2.73 0.0143
hsa-miR-9* Satterthwaite Unequal 9.19 2.88 0.0178
hsa-miR-9 Pooled Equal 17 2.64 0.0173
hsa-miR-9 Satterthwaite Unequal 9.69 2.78 0.0201
hsa-miR-27a Pooled Equal 17 -3.17 0.0056
hsa-miR-27a Satterthwaite Unequal 8.74 -3.02 0.0151
hsa-miR-24 Pooled Equal 17 -2.66 0.0164
hsa-miR-24 Satterthwaite Unequal 8.22 -2.52 0.0349
hsa-miR-29b Pooled Equal 17 -2.18 0.0439
hsa-miR-29b Satterthwaite Unequal 8.67 -2.07 0.0697
hsa-miR-23a Pooled Equal 17 -3.43 0.0032
hsa-miR-23a Satterthwaite Unequal 8.97 -3.26 0.0098
hsa-miR-29a Pooled Equal  -2.39 0.0287
hsa-miR-29a Satterthwaite Unequal 8.9 -2.27 0.0493
 
 
Table 5. Three miRNA signature clusterization of 19 GSC lines 
 
 
  
    
  GSf-like GSr-like Total
     
GSf-like  10 0 10
  100.00 0.00 100.00
  
GSr-like  1 8 9
  11.11 88.89 100.00
  
Total  11 8 19
  57.89 42.11 100.00
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Table 6. Three miRNA signature clusterization of 37 GSC lines 
 
 
  Training set 
  GSr-like  GSf-like  Total 
       
GSr-like  7 0 7 
100.00% 0.00%  
 
GSf-like  0 9 9 
0.00% 100.00%  
 
Total  7 9 16 
Test set 
  GSr-like  GSf-like  Total 
       
GSr-like  7 0 7 
100 .00% 0.00%  
 
GSf-like  1 13 14 
7.10% 92.90%  
 
Total  7 14 21 
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Table 7. Three miRNA signature clusterization of TCGA patients 
 
 
Training set 
  
M P  Total
   
M 64 6  70
91.4% 8.6%  
 
P 5 54  59
8.5% 91.5%  
 
Total 
 
69 60  129
Test set 
  
M P  Total
   
M 30 8  38
78.9% 21.1%  
 
P 7 31  38
18.4% 81.6%  
 
Total 
 
37 39  76
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